Compare NGS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGS | TRDA |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.6M | 404.4M |
| IPO Year | 2006 | 2021 |
| Metric | NGS | TRDA |
|---|---|---|
| Price | $37.29 | $11.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $39.00 | $20.00 |
| AVG Volume (30 Days) | 132.1K | ★ 207.2K |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | 260.53 | ★ 940.00 |
| EPS | ★ 1.25 | N/A |
| Revenue | $156,742,000.00 | ★ $210,782,000.00 |
| Revenue This Year | $9.83 | N/A |
| Revenue Next Year | $14.49 | $21.02 |
| P/E Ratio | $29.98 | ★ N/A |
| Revenue Growth | 29.36 | ★ 63.38 |
| 52 Week Low | $16.73 | $4.93 |
| 52 Week High | $38.37 | $13.82 |
| Indicator | NGS | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 67.26 | 50.43 |
| Support Level | $35.51 | $10.48 |
| Resistance Level | $38.37 | $11.43 |
| Average True Range (ATR) | 1.18 | 0.74 |
| MACD | 0.17 | -0.04 |
| Stochastic Oscillator | 83.07 | 48.47 |
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.